

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028487 A1

(51) International Patent Classification:

A61K 38/18 (2006.01) A61P 25/00 (2006.01)
A61P 27/16 (2006.01)

(21) International Application Number:

PCT/EP2023/071698

(22) International Filing Date:

04 August 2023 (04.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22188990.0 05 August 2022 (05.08.2022) EP

(71) Applicant: DOMPE' FARMACEUTICI SPA [IT/IT];
VIA SANTA LUCIA 6, 20121 MILANO (IT).

(72) Inventors: CASTELLI, Vanessa; 67100 L'Aquila (IT).
ARAMINI, Andrea; C/O DOMPE' FARMACEUTICI
SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). BRAN-
DOLINI, Laura; c/o Dompé farmaceutici Spa, Via Cam-
po di Pile, snc, 67100 L'Aquila (IT). COCCHIARO,
Pasquale; 80100 Napoli (IT). ROMEO, Tiziana; C/
O Dompé farmaceutici Spa, Via Campo di Pile, 67100
L'Aquila (IT). DETTA, Nicola; C/O DOMPE' FARMA-
CEUTICI SPA, Via Pietro Castellino, 111, 80131 Napoli
(IT). APPARENTE, Lucia; Via Campo di Pile, 67100
L'Aquila (IT). MATTIOLI, Simone; 67100 L'Aquila (IT).
CATTANI, Franca; 67100 L'Aquila (IT). MANTELLI,
Flavio; C/O DOMPE' FARMACEUTICI SPA, Via Campo
di Pile, snc, 67100 L'Aquila (IT). ALLEGRETTI, Mar-
cello; C/O DOMPE' FARMACEUTICI SPA, Via Campo di
Pile, snc, 67100 L'Aquila (IT).

(74) Agent: MAURI, Elisabetta Maria Ester; C/O DOMPE'
FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121
MILANO (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: INTRANASAL ADMINISTRATION OF NGF FOR THE TREATMENT OF SENSORINEURAL HEARING LOSS

(57) Abstract: The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.

WO 2024/028487 A1